Table III.
Comparison of baseline patient characteristics
| Characteristic | RM group (n = 45) | CFU group (n = 43) | P-value |
|---|---|---|---|
| Age [years], mean (SD) | 59.7 (10.6) | 62.6 (10.5) | 0.200 |
| Female, n (%) | 12 (26.7) | 7 (16.3) | 0.230 |
| Left ventricular ejection fraction (%), mean (SD) | 29.49 (5.1) | 30.27 (4.4) | 0.471 |
| NYHA class, mean (SD): | 2.82 (0.71) | 2.88 (1.41) | 0.202 |
| II, n (%) | 15 (33.3) | 9 (20.9) | |
| III, n (%) | 23 (51.1) | 30 (69.8) | |
| IV, n (%) | 7 (15.6) | 4 (9.3) | |
| Left bundle branch block, n (%) | 42 (93.3) | 40 (93.0) | 0.950 |
| Ischemic aetiology, n (%) | 25 (55.5) | 25 (58.1) | 0.860 |
| Hypertension, n (%) | 35 (77.8) | 35 (81.4) | 0.674 |
| Diabetes, n (%) | 17 (37.8) | 13 (30.2) | 0.821 |
| Hyperlipidaemia, n (%) | 11 (24.4) | 8 (18.6) | 0.543 |
| COPD, n (%) | 6 (13.3) | 8 (18.6) | 0.499 |
| Chronic kidney disease, n (%) | 2 (4.4) | 3 (6.9) | 0.673 |
| Atrial fibrillation, n (%) | 11 (24.4) | 11 (25.6) | 0.900 |
| Medications at the time of implantation: | |||
| β-receptor blockers, n (%) | 41 (91.1) | 39 (90.7) | 1.000 |
| ACEi/ARB, n (%) | 37 (82.2) | 37 (86.0) | 0.590 |
| MRA, n (%) | 31 (68.9) | 24 (55.8) | 0.310 |
| Diuretics, n (%) | 40 (88.9) | 39 (90.7) | 1.000 |
| Amiodarone, n (%) | 14 (31.1) | 9 (20.9) | 0.377 |
| Anticoagulants, n (%) | 20 (44.4) | 26 (60.5) | 0.120 |
| Antiplatelet agent, n (%) | 22 (48.9) | 20 (46.5) | 0.991 |
| Statin, n (%) | 27 (60.0) | 13 (30.2) | 0.008 |
NYHA class – New York Heart Association class, COPD – chronic obstructive pulmonary disease, ACEi – angiotensin-converting-enzyme inhibitor, ARB – angiotensin-receptor blocker, MRA – mineralocorticoid-receptor-antagonist.